Behaviour of the transgenic (mREN2)27 rat

Brain Research

Volumn 729, Issue 1, 1996, Pages 1-9

  Wilson, W ^a,d   Voigt, P ^b   Bader, M ^c   Marsden, C A ^a   Fink, H ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b Inst fur Pharmakol und Toxikologie   (Germany)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Behaviour; Elevated X maze; Open field; TGR(mREN2)27 rat; Transgenic rat

Indexed keywords

CAPTOPRIL;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CONTROLLED STUDY; HYPERTENSION; MALE; MAZE TEST; NONHUMAN; OPEN FIELD TEST; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; TRANSGENIC ANIMAL;

EID: 0030570777     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(96)00114-X     Document Type: Article

References (39)

1. [1] Bader M., Lee, M.A., Zhao, Y., Bohm, M., Bachmann, J., Sander, M., Djavidani, B., Bachmann, S., Zimmerman, F., Wilbertz, J., Zeh, K., Wagner, J., Peters, J. and Ganten, D., Renin gene expression and hypertension in transgenic animals. In M.K. Raizada, M.I, Phillips, and C. Sumners. (Eds.), Cellular and Molecular Biology of the Renin-angiotensin System, CRC press, London, 1993, pp. 60-72.
2. [2] Borawska, M., Kupryszewski, G., Witczuk, B. and Wisniewski, K., Effect of angiotensin II and its fragments: Angiotensin II (3-8)-hexapeptide and angiotensin II(4-8) pentapeptide on retrieval in passive avoidance in rats chronically treated with ethanol, Pol. J. Pharmacol. Pharm., 41 (1989) 227-230.
3. [3] Braszko, J.J. and Wisniewski, K., Some behavioural effects of captopril in rats, Gen. Pharm., 21 (1990) 851-857.
4. [4] Braszko, J.J., Wasienko, J., Koziolkiewicz, W., Janecka, A. and Wisniewski, K., The 3-7 fragment of angiotensin II is probably responsible for its psychoactive properties, Brain Res., 542 (1991) 49-54.
5. [5] Braszko, J.J., Kulakowska, A. and Wisniewski, K., Angiotensin II and its 3-7 fragment improve recognition but not spatial memory in rats. Brain Res. Bull., 37 (1995) 627-631.
6. [6] Calapai, G., Squadrito, F., Altavilla, D., Zingarelli, B., Campo, G.M., Cilia, M. and Caputi, A.P., Evidence that nitric oxide modulates drinking behaviour, Neuropharmacology, 31 (1992) 761-764.
7. [7] Costall, B., Coughlan, J., Horovits, Z.P., Kelly, M.E., Naylor, R.J. and Tomkins, D.M., The effects of ACE inhibitors captopril and SQ29,852 in rodent tests of cognition, Pharmacol. Biochem. Behav., 33 (1989) 573-579.
8. [8] Costall, B., Domeney, A.M., Gerrard, P.A., Horovitz, Z.P., Kelly, M.E., Naylor, R.J. and Tomkins, D.M., Effects of captopril and SQ29,852 on anxiety-related behaviours in rodent and marmoset, Pharmacol. Biochem. Behav., 36 (1990) 13-20.
9. [9] Croog, S.H., Levine, S., Testa, M.A., Brown, B., Bulpitt, C.J., Jenkins, C.D., Kierman, G.L. and Williams, G.H., The effects of anithypertensive therapy on the quality of life, N. Engl. J. Med., 314 (1986) 1657-1664.
10. [10] Diz, P.I. and Pirro, N.T. Differential action of angiotensin II and angiotensin-(1-7) on transmitter release, Hypertension, 19 Suppl. 2 (1992) II41-48.
11. [11] File, S.E., The interplay of learning and anxiety in the elevated plus-maze, Behav. Brain Res., 58 (1993) 199-202.
12. [12] File, S.E., Zangorssi, H., Viana, M. and Graeff, F.G., Trial 2 in the elevated plus-maze: a different form of fear?, Psychopharmacology, 111 (1993) 491-494.
13. [13] Ganten, D., Lindpaintner, K., Ganten, U., Peters, J., Zimmerman, F., Bader, M. and Mullins, J., Transgenic rats: New animal models in hypertension research, Hypertension, 17 (1991) 843-855.
14. [14] Georgiev, V., Involvement of transmitter mechanisms in the behavioural effects of angiotensin II, Pol. J. Pharmacol. Pharm., 42 (1990) 553-62.
15. [15] Holy, Z., Braszko, J. and Wisniewski, K., Psychotropic effects of angiotensin II N-terminal fragments: Asp-Val-Tyr-Ile-His and Arg-Val-Ile-His in rats, Pol. J. Pharmacol., 45 (1993) 31-41.
16. [16] Hutchinson, J.S., Mendelsohn, A.O. and Doyle, A.E., Blood pressure responses of conscious normotensive and spontaneously hypertensive rats to intracerebroventricular and peripheral administration of captopril, Hypertension, 2 (1980) 546-550.
17. [17] Jones, D.L. and Morgenson, F.A., Central injections of spiperone and GABA: attenuation of angiotensin II stimulated thirst, Can. J. Physiol. Pharmacol., 60 (1983) 720-726.
18. [18] Koeler, M., Krause, H.P., Hoffmeister, F. and Ganten, D., Endogenous brain angiotensin II disrupts passive aviodance behaviour in rats, Neurosci. Lett., 14 (1975) 71-75.
19. [19] Lee, M., Bohm, M., Kim, S., Bachmann, S., Bachmann, J., Bader, M. and Ganten, D., Differential gene expression of renin and angiotensinogen in the transgenic rat TGR (mREN-2)27, Hypertension, 25 (1995) 570-80.
20. [20] Lemmer, B., Mattes, A., Bohm, M. and Ganten, D., Circadian blood pressure variation in transgenic hypertensive rats, Hypertension, 22 (1993) 97-101.
21. [21] McBlane, J.W. and Handley, S.L., Effects of two stressors on behaviour in the elevated X-maze: preliminary investigation of their interaction with 8-OH-DPAT, Psychopharmacology, 116 (1994) 173-182.
22. [22] Mondadoori, C. and Etienne, P., Nootropic effects of ACE inhibitors in mice, Psychopharmacology, 100 (1990) 301-307.
23. [23] Morgan, J.M. and Routtenberg, A., Angiotensin injected into the neostriatum after learning disrupts retention performance, Science, 196 (1977) 87-89.
24. [24] Moriguchi, A., Ferrario, C.M., Brosnihan, K.B., Ganten, D. and Morris, M., Differential regulation of central vasopressin in transgenic rats harbouring the mouse Ren-2 gene, Am. J. Physiol., 267 (1994) R786-791.
25. [25] Mullins, J.J., Peters, J. and Ganten, D., Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene, Nature, 344 (1990) 541-544.
26. [26] Nicoletta, P., Pochieri, M., Losi, E. and Caputi, A.P., Interaction between renin-angiotensin system and cholinergic system in brain, Neuropharmacology, 22 (1983) 1269-1275.
27. [27] Fellow, S., Chopin, P., File, S.E. and Briley, M., Validation of open: closed arms entries in an elevated plus-maze as a measure of anxiety in the rat., J. Neurosci. Methods, 14 (1985) 149-167.
28. [28] Peters, J,. Munter, K,. Bader, M., Hackenthal, E., Mullins, J.J. and Ganten, D., Increased adrenal renin in transgenic hypertensive rats, TGR (mREN2)27, and its regulation by cAMP, angiotensin II and calcium, J. Clin. Invest., 91 (1993) 742-747.
29. 1 receptors in the supraoptic nucleus, J. Pharmacol. Exp. Ther., 267 (1993) 567-574.
30. [30] Reiss, L.C., Ramalho, M.J. and Antunes-Rodrigues, J., Brain serotonergic stimulation reduces the water intake induced by systemic and central beta-adrenergic stimulation, Braz. J. Med. Biol. Res., 25 (1992) 529-536.
31. [31] Sander, M., Bader, M., Djavidani, B., Maser-Gluth, C., Vecsei, P., Mullins, J., Ganten, D. and Peters, J., The role of the adrenal gland in the hypertensive transgenic rats TGR(mREN2)27, Endocrinology, 131 (1992) 807-814.
32. [32] Senanayake, P. Des, Moriguchi, A., Kumugai, H., Ganten, D., Ferrarrio, C.M. and Brosnihan, K.B., INcreased expression of angiotensin peptides in the brain of transgenic hypertensive rats, Peptides, 15 (1994) 919-926.
33. [33] Soderpalm, B., The SHR exhibits less 'anxiety' but increased sensitivity to the anticonflict effect of clonidine compared to normotensive controls, Pharmacol. Toxicol., 65 (1989) 381-386.
34. [34] Tokita, Y., Franco-Saenz, R., Reimann, E.M. and Mulrow, P.J., Hypertension in the transgenic rat TGR(mREN-2)27 nay be due to enhanced kinetics of the reaction between mouse renin and rat angiotensin, Hypertension, 23 (1994) 422-427.
35. [35] Ungerstedt, U., Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system, Acta Physiol. Scand., 82 (1971) 95-122.
36. [36] Widdop, R.E., Gardiner, S.M. and Bennett, T., Effect of angiotensin II AT1-or AT2-receptor antagonists on drinking evoked by angiotensin II or water deprivation in rats, Brain Res., 648 (1994) 46-52.
37. [37] Wisniewski, K., Borawska, M. and Halina, C.A.R., The effects of angiotensin II and its fragments on post-alcohol impairments in learning and memory, Pol. J. Pharmacol., 45 (1993) 23-29.
38. [38] Wright, J.W., Roberts, K.A. and Harding, J.W., Angiotensin II(3-8) (ANG IV) hippocampal binding: Potential role in the facilitation of memory, Brain Res. Bull., 32 (1993) 497-502.
39. [39] Wright, J.W. and Harding, J.W., Brain angiotensin receptor subtypes in the control of physiological and behavioural responses, Neurosci. Biobehav. Rev., 18 (1994) 21-53.